The Annals
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


Drug Intelligence & Clinical Pharmacy: Vol. 19, No. 10, pp. 729-731.
© 1985 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by True, B.
Right arrow Articles by Burns, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by True, B.
Right arrow Articles by Burns, E.


Research Articles

Routine pertussis immunization

BL True and EA Burns

The benefits and risks of both the vaccine for pertussis and the disease itself are reviewed in this article. Unlike with the smallpox vaccine, it seems unlikely that a vaccine will be developed to eradicate pertussis completely, since most confer only a short-term immunity. A longitudinal study was undertaken to compare the mortality and morbidity rates of pertussis with the adverse reaction rate of the vaccination program. Risks of the vaccination, such as erythema, drowsiness, and vomiting are well known. However, the issue of neurologic difficulties has surfaced and disagreement exists. Some association does seem to exist between the vaccine and neurologic problems; however, the morbidity and mortality of whooping cough is of a greater health consequence than these rare neurologic reactions.





homecopy help contact us subscription past issues search current issue
Copyright © 1985 by Harvey Whitney Books Company.